Press Releases

- Accomplished Important Asset Monetization Milestones with the Distribution of Evofem Biosciences Shares to PDL Stockholders and the Anticipated Sale of Noden to Stanley Capital   - Announced the Filing of a Form 10 with SEC for Potential Spin-off of LENSAR   - Continues to Seek Potential

INCLINE VILLAGE, Nev. , July 30, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its second quarter 2020 financial results for the period ended June 30, 2020 , on Thursday, August 6, 2020 , after market close.

INCLINE VILLAGE, Nev. , July 30, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing of a definitive agreement for the sale of 100% of the outstanding stock in its wholly owned subsidiaries Noden Pharma DAC and Noden USA (collectively " Noden ")

INCLINE VILLAGE, Nev. , May 21, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that it has completed its previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc.

INCLINE VILLAGE, Nev. , May 18, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the final distribution ratio for the previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc.

Provides Update to Asset Monetization Plan Discusses Impact of COVID-19 on Operations and Monetization Plan - Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today - INCLINE VILLAGE, Nev. , May 7, 2020 /PRNewswire/ --  PDL BioPharma, Inc.

INCLINE VILLAGE, Nev. , May 5, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that the Company's Board of Directors has approved a distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc.

INCLINE VILLAGE, Nev. , April 30, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its first quarter 2020 financial results for the period ended March 31, 2020 , on Thursday, May 7, 2020 , after market close.

- 2019 Revenue Guidance Exceeded - - Monetization Process Underway - - PDL Board Approved Plan of Complete Liquidation and Plans to Seek Stockholder Approval for Dissolution of the Company - - Targeting to File a Certificate of Dissolution under Delaware Law by Year-End 2020 - - Conference Call at

INCLINE VILLAGE, Nev. , March 9, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced the appointment of Edward A. Imbrogno as the Company's Vice President and Chief Financial Officer. Mr. Imbrogno joined PDL as Vice President of Finance in October 2018

INCLINE VILLAGE, Nev. , March 4, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its 2019 fourth quarter and full year financial results for the period ended December 31, 2019 , on Wednesday, March 11, 2020 , after market close.

Appoints New Independent Director Alan L. Bazaar to its Board of Directors INCLINE VILLAGE, Nev. , Feb. 28, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced it has entered into a cooperation agreement with Engine Capital Management LP (together with

INCLINE VILLAGE, Nev. , Feb. 25, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that Dominique Monnet , PDL's president and chief executive officer, will present at the Cowen and Company 40 th Annual Health Care Conference on Tuesday, March 3, 2020 at

Director Elizabeth O'Farrell Named Chairperson of the Board Chairperson Dr. Harold E. Selick to Retire from Board by Year-End Director Paul Sandman to Retire at 2020 Annual Meeting Board to be Reduced to Six Directors Following 2020 Annual Meeting INCLINE VILLAGE, Nev. , Dec.

INCLINE VILLAGE, Nev. , Dec. 16, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announced today that its Board of Directors has authorized a $75 million increase to the $200 million common stock and convertible notes repurchase authorization that was previously